NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Subfoveal choroidal neovascularization secondary to age-related macular degeneration
Date of first enrollment	11/11/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : SK-1011 INN of investigational material : Therapeutic category code : 131 Agents for ophthalmic use Dosage and Administration for Investigational material : oral administration, 60mg BID (twice a day) control material(s) Generic name etc : Placebo INN of investigational material : Therapeutic category code : --- Other Dosage and Administration for Investigational material : oral administration, BID (twice a day)

Outcome(s)

Primary Outcome	Efficacy and safety
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 50age old
Age maximum	Not applicable
Gender	Both
Include criteria	1) Age-related macular degeneration patients diagnosed with subfoveal choroidal neovascularization in the study eye 2) Patients who have a BCVA ETDRS score between 73 and 24 letters in the study eye inclusive (approximately 0.5 to 0.06) 3) Patients who are capable of giving written informed consent
Exclude criteria	1) Use of systemic anti-VEGF medication 2) Prior treatment in the study eye with anti-VEGFs, verteporfin, steroids, or laser photocoagulation within certain periods of time 3) Presence of retinal angiomatous proliferation (RAP) in the study eye 4) Medical conditions such as cancer, serious liver, renal cardiac disease